


PHYTOCHEMISTRY AND PHARMACOGNOSY



Phytochemistry and Pharmacognosy - Volume 1

No. of Pages: 374

ISBN: 978-1-78021-046-9 (eBook)

ISBN: 978-1-78021-546-4 (Print Volume)

Phytochemistry and Pharmacognosy - Volume 2

No. of Pages: 364

ISBN: 978-1-78021-047-6 (eBook)

ISBN: 978-1-78021-547-1 (Print Volume)

For more information of e-book and Print Volume(s) order, please [click here](#)

Or [contact : eolssunesco@gmail.com](mailto:eolssunesco@gmail.com)

CONTENTS

VOLUME I

Preface x

Phytochemistry and Pharmacognosy 1

Massuo J. Kato, *University of São Paulo, São Paulo, 5508-000, SP, Brazil*

John M. Pezzuto, *University of Hawaii at Hilo, College of Pharmacy, Hilo, Hawaii, USA 96720*

1. Introduction
2. Biosynthetic origin and role of natural products
 - 2.1. Lipid-like Compounds
 - 2.2. Phenolic Compounds
 - 2.3. Alkaloids
3. Extraction and analysis of natural products
4. Future trends of natural products and bioprospecting programs
5. Implication in uses and conservation of biodiversity
6. Conclusions

Ethnobotany of Natural Products 41

D. D. Soejarto, C. Gyllenhaal, M. C. Riley and H. Zhang, *Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, U.S.A.*

1. Introduction
2. History of Ethnobotany
 - 2.1. Western Sources (Written Tradition)
 - 2.2. Non-Western Sources (Written Tradition)
 - 2.3. Oral Tradition
3. Age of Discovery
4. Modern Ethnobotany
 - 4.1. Early Ethnobotanical Studies – Intersection with Cultural Anthropology
 - 4.2. Expanded Fieldwork
 - 4.3. Role of Anthropology
 - 4.4. Ethnobotany and the Discovery of New Medicines
 - 4.5. The Continuing Search: Contemporary Ethnobotanical Field Methods
 - 4.5.1. Field Interviews
 - 4.5.2. Prior Informed Consent
 - 4.5.3. Documentation
 - 4.5.4. Data Elements in Medicinal Plant Interview
 - 4.5.5. Academic Research and Bioprospecting
 - 4.5.6. Grass Roots Community Oriented Research
5. Contributions of Ethnobotany to Modern Medicine
 - 5.1. Drug Discovery since the CBD
 - 5.2. Urban Ethnobotany and Modern Medicine
6. Challenges Facing Ethnobotany-Guided Natural Product Drug Discovery
 - 6.1. Commercial Valuation of Economic and Medicinal Plants
 - 6.2. Intellectual Property Rights and Traditional Botanical Knowledge Systems
 - 6.3. Access to Genetic Resources and Benefit Sharing
 - 6.4. Research and Funding for Ethnobotany
 - 6.5. Ethics of Ethnobotanical Research
7. Conclusions

Occurrence and Function of Natural Products in Plants**93**

Michael Wink, *Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, INF 364, 69120 Heidelberg, Germany*

1. Classes and Numbers of Secondary Metabolites (SM)
2. Occurrence and Properties of Major Groups of SM
3. Physiology of Secondary Metabolism: Biosynthesis, Transport and Storage of SM
4. Ecological Roles of SM
5. Molecular Modes of Action of SM
6. Chemosystematics of Plants and Distribution Patterns of SM
7. Origins and Evolution of Plant Secondary Metabolism
8. Conclusions

Alkaloids and their Biosynthesis**125**

Geoffrey A. Cordell, *Natural Products Inc., Evanston, IL, U.S.A*

Taylor Choi, *Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, U.S.A.*

1. Introduction
2. Alkaloids Derived from Ornithine
3. Alkaloids Derived from Phenylalanine/Tyrosine
 - 3.1. Tetrahydrobenzylisoquinoline Alkaloids and Derivatives
 - 3.2. Phenethylisoquinoline Alkaloids
 - 3.3. Amaryllidaceae Alkaloids
 - 3.4. C₆-C₁ Alkaloids
 - 3.5. Cephaelis Alkaloids
4. Alkaloids Derived from Tryptophan
 - 4.1. Simple Indole Alkaloids
 - 4.2. Manzamine Alkaloids
 - 4.3. Ergot Alkaloids
 - 4.4. Monoterpenoid Indole Alkaloids
 - 4.4.1. Corynanthe to Secodine Pathway and Branches
 - 4.4.2. Secodine to the *Aspidosperma*, *iboga* and *Eburnea* skeleta
 - 4.4.3. Camptothecin (189)
 - 4.4.4. Quinine (187) and Quinidine (188)
5. Alkaloids Derived from Miscellaneous Amino Acids
 - 5.1. Nicotinic Acid Derived
 - 5.2. Porphine Alkaloids
6. Alkaloids Derived from a Xanthine Nucleus
7. Other Important Alkaloid Groups
 - 7.1. Pyrrolizidine Alkaloids
 - 7.2. Quinolizidine Alkaloids
 - 7.3. Indolizidine Alkaloids
 - 7.4. Anthranilic Acid-Derived Alkaloids
 - 7.5. Histidine-Derived Alkaloids
 - 7.6. Terpenoid Alkaloids
 - 7.6.1. Monoterpene Alkaloids
 - 7.6.2. Diterpene Alkaloids
 - 7.6.3. Steroidal Alkaloids
 - 7.6.4. Triterpene Alkaloids
8. Conclusions

Plant Terpenes**196**

Hongjie Zhang, *Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, the University of Illinois at Chicago, Illinois 60612, USA*

Minghua Qiu, *State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204 P. R. China*

Yegao Chen, *Department of Chemistry, Yunnan Normal University, Kunming 650092, P. R. China*
Jinxiong Chen, *State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204 P. R. China*
Yun Sun, *State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204 P. R. China*
Cuifang Wang, *State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204 P. R. China*
Harry H.S. Fong, *Program for Collaborative Research in the Pharmaceutical Sciences, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, the University of Illinois at Chicago, Illinois 60612, USA*

1. Introduction
2. Hemiterpenes
3. Monoterpenes
4. Sesquiterpenes
 - 4.1. Farnesanes
 - 4.2. Monocyclic Sesquiterpenes
 - 4.3. Bicyclic Sesquiterpenes
 - 4.4. Tricyclic and Polycyclic Sesquiterpenes
5. Diterpenes
 - 5.1. Phytanes
 - 5.2. Cyclophytanes
 - 5.3. Bicyclophytanes
 - 5.3.1. Labdanes
 - 5.3.2. Clerodanes
 - 5.3.3. Ginkgolides
 - 5.4. Tricyclophytanes
 - 5.4.1. Abietanes
 - 5.4.2. Pimaranes and Isopimaranes
 - 5.4.3. Cassanes
 - 5.4.4. Podocarpanes
 - 5.5. Tetracyclophytanes
 - 5.5.1. Beyeranes
 - 5.5.2. Kauranes
 - 5.5.3. Atisanes
 - 5.5.4. Gibberellanes
 - 5.5.5. Grayanotoxanes
 - 5.6. Macrocyclic Diterpenoids
 - 5.6.1. Cembranes
 - 5.6.2. Casbanes
 - 5.6.3. Phorbanes
 - 5.6.4. Daphnanes
 - 5.6.5. Jatrophanes
 - 5.6.6. Lathyranes
 - 5.6.7. Taxanes
6. Sesterterpenes
7. Triterpenes
 - 7.1. Tetracyclic Triterpenes
 - 7.1.1. Lanostanes
 - 7.1.2. Cycloartane
 - 7.1.3. Cucurbitane
 - 7.1.4. Dammarane
 - 7.1.5. Tirucallane, Euphane, Apo-Tirucallane, Limonoid and Quassiane
 - 7.2. Pentacyclic Triterpenes
 - 7.2.1. Oleanane
 - 7.2.2. Friedelane
 - 7.2.3. Ursane
 - 7.2.4. Lupane

- 7.2.5. Hopane
- 7.2.6. Serratane
- 8. Polyterpenes
- 9. Conclusions

Natural Products from Marine Microorganisms **251**
 B. T. Murphy, K. N. Maloney and W. Fenical, *Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, California, 92093-0204 U.S.A.*

- 1. Introduction
- 2. Secondary metabolites from Gram-negative marine bacteria
 - 2.1. Proteobacteria
 - 2.1.1. Alpha- and Delta-Proteobacteria
 - 2.1.2. Gamma-Proteobacteria
 - 2.2. Bacteroidetes
 - 2.3. Chloroflexi
 - 2.4. Verrucomicrobia
 - 2.5. Aquificae
 - 2.6. Undescribed Gram-negative Marine Bacteria
- 3. Secondary metabolites from marine Cyanobacteria
- 4. Secondary metabolites from Gram-positive marine bacteria
 - 4.1. Firmicutes
 - 4.2. Actinobacteria (Actinomycetes)
 - 4.2.1. Streptomycetaceae
 - 4.2.2. Micromonosporaceae
 - 4.2.3. Additional Families of Actinobacteria
- 5. Secondary metabolites from marine-derived fungi
 - 5.1. Ascomycota
 - 5.1.1. Dothideomycetes
 - 5.1.2. Eurotiomycetes
 - 5.1.3. Leotiomycetes
 - 5.1.4. Sordariomycetes
 - 5.1.5. Unidentified Marine-derived Fungi
- 6. Secondary metabolites from marine phototrophic eukaryotes
- 7. Discussion / Conclusions

Index **309**

About EOLSS **315**

VOLUME II

Natural Products from Bacteria and Fungi **1**
 A. A. Leslie Gunatilaka and E. M. Kithsiri Wijeratne, *Southwest Center for Natural Products Research and Commercialization, Office of Arid Lands Studies, School of Natural Resources and the Environment, College of Agriculture and Life Sciences, University of Arizona, U S. A.*

- 1. Introduction
- 2. Terpenoids
 - 2.1. Monoterpenoids
 - 2.2. Sesquiterpenoids
 - 2.3. Diterpenoids
 - 2.4. Sesterterpenoids
 - 2.5. Triterpenoids
 - 2.6. Polyterpenoids
- 3. Polyketides

- 3.1. Quinones
- 3.2. Xanthones
- 3.3. Coumarins and isocoumarins
- 3.4. CHROMONES
- 3.5. Aflatoxins
4. Alkaloids
5. Non-ribosomal Peptides
6. Cytochalasins

Natural Products with Antimalarial Activity

28

Fred Musoke Sebisubi, *Division of Pharmaceutical Services, Ministry of Health, Kampala, Uganda.*
Department of Pharmaceutical Sciences, College of Pharmacy, University of Hawaii at Hilo, Hawaii,
USA.

Ghee T. Tan, *Department of Pharmaceutical Sciences, College of Pharmacy, University of Hawaii at*
Hilo, Hawaii, USA.

1. Introduction
2. Life cycle of *Plasmodium*
3. Established natural product antimalarial drugs
4. Antimalarial drug resistance
5. The promise of natural products
6. Antimalarial assays
7. Classes of natural products with antimalarial activity
 - 7.1. Alkaloids
 - 7.1.1. Quinoline and Isoquinoline Alkaloids
 - 7.1.1.1. Naphthylisoquinoline Alkaloids
 - 7.1.1.2. Bisbenzylisoquinoline Alkaloids
 - 7.1.1.3. Protoberberine, Phenanthridine and Aporphine Alkaloids
 - 7.1.2. Indole Alkaloids
 - 7.1.3. Miscellaneous Alkaloids from Terrestrial Sources
 - 7.1.4. Marine Alkaloids
 - 7.2. Terpenes
 - 7.2.1. Sesquiterpenes
 - 7.2.1.1. Marine Sesquiterpenoids
 - 7.2.2. Triterpenes
 - 7.2.3. Diterpenes
 - 7.2.3.1. Marine Diterpenoids
 - 7.2.3.2. Marine Endoperoxides
 - 7.2.4. Miscellaneous Terpenoid Compounds
 - 7.2.4.1. Quassinoids
 - 7.2.4.2. Limonoids
 - 7.3. Flavonoids
 - 7.3.1. Chalcones
 - 7.4. Quinones
 - 7.5. Xanthones and Coumarins
 - 7.6. Peptides
 - 7.7. Phenols
 - 7.8. Lignans
8. Conclusions

Cancer Chemoprevention

82

Jacquelyn M. Guilford and John M. Pezzuto, *University of Hawaii at Hilo, College of Pharmacy, Hilo,*
Hawaii, USA 96720

1. Introduction
 - 1.1. Cancer
 - 1.2. Cancer Risk Factors
 - 1.3. Cancer Prevention

2. Cancer Chemoprevention Drugs
 - 2.1. Selective Estrogen Receptor Modulators (SERMs)
 - 2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
 - 2.3. Aromatase Inhibitors
 - 2.4. OTHER
3. Natural Product Chemopreventive Agents
 - 3.1. Natural Product Sampling and High Throughput Screening
 - 3.2. Dietary Chemopreventive Agents
 - 3.2.1. Curcumin
 - 3.2.2. Epigallocatechin Gallate (EGCG)
 - 3.2.3. Lycopene
 - 3.2.4. Organosulfur Compounds
 - 3.2.5. Resveratrol
 - 3.2.6. Selenium
 - 3.2.7. Silymarin
 - 3.2.8. Soy
 - 3.2.9. Vitamin D
 - 3.2.10. Vitamin E
 - 3.2.11. Other
 - 3.3. Combination Chemoprevention
4. The Future of Cancer Chemoprevention
 - 4.1. Biomarkers
 - 4.2. Personalized Cancer Chemoprevention
 - 4.3. Limitations of Moving Forward
5. Conclusion

Natural Products as Sources of Antitumor Agents

119

G. M. Cragg and D. J. Newman, *Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Maryland 21702-1201, U S A*

1. Introduction
2. Antitumor Agents from Terrestrial Plant Sources
 - 2.1. Plant-Derived Anti-Cancer Agents in Clinical Use (Figure 1)
 - 2.2. Plant-Derived Agents in Clinical Development (Figure 2)
 - 2.3. Plant-Derived Agents in Preclinical Development (Figure 3)
 - 2.4. The Role of Endophytes
3. Antitumor Agents Derived from Marine Sources
 - 3.1. Marine-Derived Drugs in Clinical Use (Figure 4)
 - 3.2. Marine-Derived Agents in Clinical Development (Figure 4)
 - 3.3. Marine-Derived Agents Withdrawn from Clinical Trials (Figure 5)
 - 3.4. Marine-Derived Agents in Preclinical Development (Figure 6)
 - 3.5. The Role of Marine Symbionts
4. Antitumor Agents from Microbial Sources
 - 4.1. Microbial-Derived Drugs in Clinical Use (Figure 7)
 - 4.2. Microbial-Derived Agents in Clinical Development (Figure 8)
 - 4.3. Microbial-Derived Agents in Preclinical Development (Figure 9)
 - 4.4. The Impact of Genomics on Drug Discovery and Development
5. Targeted Delivery
6. Conclusions

Microbial Transformations of Natural Products

149

S. R. Gopishetty, *Center for Biocatalysis and Bioprocessing, The University of Iowa, U. S. A*
 M. T. Louie, *Department of Chemical and Biochemical Engineering, The University of Iowa, U. S. A*
 M. V. Subramanian, *Center for Biocatalysis and Bioprocessing, Department of Chemical and Biochemical Engineering The University of Iowa, U. S. A*

1. Introduction
2. Biotransformations of Terpenoids

3. Biotransformations of Steroids
 - 3.1. Dehydrogenation
 - 3.2. Hydroxylation
 - 3.3. Δ^1 -Dehydrogenation
4. Biotransformation of Alkaloids
 - 4.1. Classification of Alkaloids
 - 4.2. Microbial Transformations of Tropane Alkaloids
 - 4.3. Microbial Transformations of Benzyloisoquinoline Alkaloids
 - 4.4. Microbial Transformations of Quinoline Alkaloids.
 - 4.5. Microbial Transformations of Pyridine Alkaloids
 - 4.6. Microbial transformations of caffeine and related alkaloids
5. Biotransformation of Flavonoids
6. Conclusions

Natural Products from Plants as Insecticides

177

John Thor Arnason, *Centre for Research in Environmental Genomics, University of Ottawa, Ottawa ON K1N 6N5*

Steven R. Sims, *BASF Corp. St Louis MO 63122.*

Ian M Scott, *Southern Crop Protection and Food Research Centre, Agriculture and Agrifood Canada, London ON, N5V 4T3*

1. Introduction
2. Traditionally used botanical insecticides
3. Neem, azadirachtin and related limonoids
4. Essential oils
5. Pepper insecticides
6. Other experimental botanical insecticides
7. Conclusions

The origin of pharmaceuticals

195

Eliezer J. Barreiro, Carlos Alberto M. Fraga and Lidia M. Lima, *Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio®) Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, CCS, Cidade Universitária, ZIP 21944-910 Rio de Janeiro, RJ, Brazil*

1. Medicinal Chemistry definition and the role of lead-compound in drug discovery
2. Natural products as medicines and drugs candidates
 - 2.1. Plants as a Source of Drugs
 - 2.2. Microorganisms as a Source of Drugs
 - 2.3. Marine as Sources of Drugs
3. Conclusions

Natural Products as Sources of Spices, Dyes and Cosmetics

233

P. Di Mascio, *Department of Biochemistry, University of São Paulo, Brazil*

L. F. Yamaguchi, *Department of Fundamental Chemistry, University of São Paulo, Brazil*

1. Spices
 - 1.1. Introduction
 - 1.2. Cinnamon
 - 1.3. Pepper
 - 1.4. Mustard
 - 1.5. Nutmeg
 - 1.6. Vanilla
 - 1.7. Chili
 - 1.8. Clove
 - 1.9. Ginger
 - 1.10. Bay leaf
 - 1.11. Saffron
 - 1.12. Mint Family: Lamiaceae

- 1.12.1. Mint
- 1.12.2. Basil
- 1.12.3. Rosemary, Sage and Oregano
- 2. Natural Dyes
 - 2.1. Introduction
 - 2.2. Sources of Natural Dyes
 - 2.2.1. Plants
 - 2.2.1.1. Indigo
 - 2.2.1.2. Madder
 - 2.2.1.3. *Caesalpinia*
 - 2.2.1.4. Annatto
 - 2.2.1.5. Safflower
 - 2.2.1.6. Turmeric
 - 2.2.2. Animals
 - 2.2.2.1. Tyrian purple
 - 2.2.3. Insects
 - 2.2.3.1. Cochineal
- 3. Natural sources for cosmetic ingredients
 - 3.1. Introduction
 - 3.2. Vitamins
 - 3.2.1. Vitamin A
 - 3.2.2. Vitamin C
 - 3.2.3. Vitamin E
 - 3.2.4. Pro-vitamin B5
 - 3.3. Carotenoids
 - 3.3.1. β -Carotene
 - 3.3.2. Lycopene
 - 3.4. Miscellaneous
 - 3.4.1. Azulene
 - 3.4.2. Kojic acid
 - 3.4.3. α -(-)-Bisabolol
 - 3.4.4. Soy
 - 3.4.5. Aloe Vera
 - 3.5. Moisturizing agents
- 4. Conclusion

Medicinal Plants and Phytomedicines

271

Rosendo Augusto Yunes, *Curso de Pós-Graduação em Química, Universidade Federal de Santa Catarina (UFSC), 88.040-900, Florianópolis-SC, Brazil.*

Rivaldo Niero and Valdir Cechinel Filho, *Núcleo de Investigações Químico-Farmacêuticas (NIQFAR) e Programa de Mestrado em Ciências Farmacêuticas, Universidade do Vale do Itajaí (UNIVALI), 88.302-202, Itajaí-SC-Brazil.*

- 1. Introduction
- 2. Quality control of phytomedicines
 - 2.1. Quality and efficacy of plant material
 - 2.2. Production methods
- 3. Medicinal teas today
- 4. Modern phytotherapy
 - 4.1. New scientific screening
 - 4.2. Mechanism of action
 - 4.3. Synergy
- 5. Some selected medicines
 - 5.1. *Ginkgo biloba* (gingko)
 - 5.2. *Serenoa repens* (saw palmetto)
 - 5.3. *Valeriana officinalis* (valerian)
 - 5.4. *Hypericum perforatum* (hypericum)
 - 5.5. *Allium sativum* (garlic)

- 5.6. *Piper methysticum* (kava kava)
- 5.7. *Glycine max* (soy)
- 5.8. *Matricaria chamomilla* (chamomile)
- 5.9. *Maytenus ilicifolia* (espinheira-Santa)
- 5.10. *Ilex paraguayensis* (mate)
- 5.11. *Cynara scolymus* (artichoke)
- 5.12. *Phyllanthus niruri* (quebra-pedra)
- 6. A case study: development of a phytomedicine from biodiversity
- 7. Conclusions

Index **299**

About EOLSS **305**